产品详情
-
Product Name
Anti-CTLA-4 [Ipilimumab]
-
Gene ID
-
-
SwissProt ID
-
-
Gene Name
-
-
Alternative Names
Ctla4; Cytotoxic T-lymphocyte protein 4; CD152
-
Background
Ipilimumab biosimilar is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA4 is an inhibitory receptor found at the surface of T-cells responsible for the downregulation of the immune response. Upon binding to CTLA4, ipilimumab acts as an immune checkpoint inhibitor and promotes T-cell activation against cancer cells. Ipilimumab was first approved by the FDA in 2011 for the treatment of melanoma and is now used to treat colorectal cancer, hepatocellular carcinoma, advanced melanoma, and renal cell carcinoma. It is currently under investigation for other types of advanced and metastatic cancers.
-
Research Field
Epigenetics and Nuclear Signaling
-
Product Categories
Primary antibody
-
Host
Humanized
-
Reactivity
Human
-
Application
Functional Assay
-
Dilution Ratio
-
-
Molecular Weight
-
-
Clonality
Monoclonal Antibody
-
Clonality No.
-
-
Isotype
IgG1
-
Immunogen
-
-
Purification
Affinity Purified
-
Conjugation
Unconjugated
-
Modification
Unmodified
-
Form
Liquid
-
Buffer System
0.01M PBS, pH 7.2
-
Storage
This solution is stable for at least 4 weeks when stored at 2-8°C. For long term storage aseptically aliquot and store at –80°C. Avoid repeated freeze/thaw cycles.
应用缩写
WB:蛋白质印迹法IHC-P:石蜡切片样本的免疫组织化学法IHC-F:冰冻切片样本的免疫组织化学法ICC/IF:免疫细胞荧光 IP:免疫沉淀法FC:流式细胞术ChIP:染色质免疫沉淀法ELISA:酶联免疫吸附测定
正能生物产品售后保障范围仅限官网产品详情页中“应用”一栏写明的实验应用，请参照上方的缩写含义，仔细对照后选择合适的产品。